Labcorp (LH) EVP Caveney converts RSUs and withholds shares for tax obligations

Rhea-AI Filing Summary

Labcorp Holdings Inc. executive Brian J. Caveney, EVP and President of Enterprise Diagnostics, CMO & CSO, reported equity award activity in company stock. On February 11, 2026, he exercised 740 Restricted Stock Units, converting them into 740 shares of Common Stock at an exercise price of $0 per share.

To cover tax withholding obligations related to this vesting, 211 shares of Common Stock were withheld at a price of $289.89 per share, coded as a disposition for tax payment rather than an open-market sale. After these transactions, he directly held 31,606.9234 shares of Common Stock and 4,170 Restricted Stock Units, which vest in three equal annual installments beginning on February 11, 2026.

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Caveney Brian J

(Last) (First) (Middle)

531 SOUTH SPRING STREET

(Street)

BURLINGTON NC 27215

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
LABCORP HOLDINGS INC. [ LH ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	EVP, Pres of ED, CMO & CSO

3. Date of Earliest Transaction (Month/Day/Year)
02/11/2026

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	02/11/2026		M		740	A	(1)	31,817.9234	D
Common Stock	02/11/2026		F(2)		211	D	$289.89	31,606.9234	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Restricted Stock Unit	(1)	02/11/2026		M			740	(3)	(3)	Common Stock	740	$0	4,170(4)	D

Explanation of Responses:

1. Each Restricted Stock Unit represents the contingent right to receive one share of Labcorp Holdings Inc. Common Stock.

2. Stock withholding to satisfy tax withholding obligations.

3. The Restricted Stock Units that have vested were part of a grant that vests in three equal annual installments beginning on February 11, 2026.

4. This number reflects the aggregate number of Restricted Stock Units held by the reporting person.

	/s/ Kathryn W. Kyle, Attorney-in-Fact for Brian J. Caveney	02/13/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

What insider transaction did Labcorp (LH) executive Brian J. Caveney report?

Brian J. Caveney reported exercising 740 Restricted Stock Units into 740 shares of Labcorp Common Stock. The RSUs vested as part of an equity grant, increasing his direct share holdings while maintaining additional unvested RSUs for future periods.

Did the Labcorp (LH) insider sale involve open-market selling of shares?

The disposition was for tax withholding, not an open-market sale. Labcorp withheld 211 Common Stock shares at $289.89 per share to satisfy tax obligations arising from RSU vesting, a common administrative step in equity compensation.

How many Labcorp (LH) Common Stock shares does Brian J. Caveney own after the transactions?

Following the February 11, 2026 transactions, Brian J. Caveney directly holds 31,606.9234 Labcorp Common Stock shares. This figure reflects both the RSU conversion into shares and the shares withheld to cover related tax liabilities.

What are the details of the Restricted Stock Units held by the Labcorp (LH) executive?

After the reported activity, Caveney holds 4,170 Restricted Stock Units. These RSUs come from a grant that vests in three equal annual installments beginning on February 11, 2026, each unit representing a contingent right to one Common Stock share.

What transaction codes appear in the Labcorp (LH) Form 4 filing?

The filing shows code M for the exercise or conversion of derivative securities, reflecting RSU vesting into 740 Common Stock shares, and code F for 211 shares withheld to pay tax obligations, classified as a disposition by delivering shares.

Is Brian J. Caveney a major shareholder or officer at Labcorp (LH)?

Caveney is reported as an officer of Labcorp Holdings Inc., serving as EVP, President of Enterprise Diagnostics, Chief Medical Officer, and Chief Scientific Officer. He is not identified in the filing as a director or 10% beneficial owner.